ADVANCED SOLID TUMOR

This early-phase study tested a new drug called BMS-986315, both by itself and combined with other cancer treatments, in people with advanced solid tumors. The main goals were to check the safety of the drug and see what side effects occurred at different doses. Researchers also …

This early-stage study tested a new drug called NB003 in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals were to find a safe dose, see how the body processes the drug, and check for any early signs that it might help shrink tu…

This was the first study in people to test a new drug called LM-108 for advanced solid tumors. It involved 78 adults whose cancer had progressed despite standard treatments. The main goals were to find a safe dose and see if the drug, given alone or with an immunotherapy, showed …

This was the first-ever study in people to test the safety of a new oral drug called MSP008-22, which is designed to fight cancer. It involved 7 adults with advanced solid tumors (like breast, ovarian, or prostate cancer) to see how their bodies handled a single dose. The main go…

This early-phase study tested the safety and best dose of a new drug called BGB-10188. It was given alone or combined with other cancer drugs to 97 patients with advanced blood cancers or solid tumors that had returned or stopped responding to prior treatments. The main goal was …

This first-in-human study tested a new drug called PRT3789, both alone and combined with the chemotherapy docetaxel, in people with advanced solid tumors that have a specific SMARCA4 gene mutation. The main goals were to find a safe dose, see how the body processes the drug, and …

This study tested whether combining two, three, or four different immunotherapy drugs could help control advanced prostate cancer that had stopped responding to standard hormone therapy. The trial enrolled 59 adults with this type of cancer or other advanced solid tumors. Researc…

This early-stage study tested the safety of combining two experimental drugs, vobramitamab duocarmazine and lorigerlimab, in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find a safe dose and see how the body processes …

This early-stage study tested the safety of a personalized immunotherapy for people with advanced solid tumors. Doctors collected immune cells from patients' tumors, grew more of them in a lab, and then reinfused them back into 43 participants to see if they could fight the cance…

This early-phase study tested a new oral drug called RP-3500 (camonsertib) in adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe and effective dose, check how the body processes the drug, and see if it could he…

This study tested whether combining an immunotherapy drug (durvalumab) with an epigenetic drug (tazemetostat) could help control advanced solid tumors. It enrolled 164 adults with specific advanced cancers, including pancreatic, colorectal, and soft-tissue sarcoma, who had run ou…

This early-stage study tested whether combining an experimental cancer drug with a special diet designed to lower insulin could make treatment safer and more effective. It involved 34 adults with advanced solid tumors that had specific genetic changes (PIK3CA mutations). The main…

This early-stage study tested the safety and best dose of a new two-drug immunotherapy combination (BGB-A445 plus tislelizumab) in 204 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to see how much of the drugs patients cou…

This study tested an experimental drug called LM-302 in people with advanced solid tumors that have a specific protein marker (CLDN18.2). The main goals were to find a safe dose and see if the drug shows early signs of fighting the cancer. It involved 153 adults whose cancer had …

This early-stage study tested the safety of combining two drugs, pembrolizumab and AMG386, in 62 patients with advanced solid tumors like melanoma, ovarian, kidney, or colorectal cancer. The goal was to see if the combination was safe and to find the right dose, as lab research s…

This was an early-stage study to test the safety and find the right dose of a new drug called BAT1308 for people with advanced solid tumors that had stopped responding to standard treatments. The study involved 59 participants with cancers like non-small cell lung cancer, liver c…

This early-stage study tested a new oral drug, JAB-21822, in adults with advanced solid tumors (like lung or colon cancer) that have a specific genetic change called KRAS G12C. The main goals were to find a safe dose and see if the drug, given alone or with another cancer drug (c…

This was a first-in-human study to test the safety and early effectiveness of a new drug called CHS-388 for people with advanced solid tumors. The trial enrolled 145 adults with cancers like kidney, liver, and lung cancer that had progressed after standard treatments. Researchers…

This first-in-human study tested a new experimental drug called HMBD-002, which targets a protein on cancer cells called VISTA. The trial aimed to find a safe dose and schedule for giving HMBD-002 alone and combined with the approved immunotherapy drug pembrolizumab (Keytruda®) i…

This was a very early, small study to test the safety of a new drug called BR101 in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find a safe dose for future studies by giving the drug to 15 participants and closely mon…

This study tested whether combining a blood test (liquid biopsy) with traditional tissue analysis could better identify specific genetic changes in patients with advanced non-small cell lung cancer. Researchers enrolled 581 newly diagnosed patients to compare how well each method…

This study aimed to understand how a drug for lung conditions (bosentan) affects the levels of a cancer drug (lurbinectedin) in the body. It involved 11 patients with advanced solid tumors who had run out of standard treatment options. Patients received the cancer drug both alone…